tradingkey.logo
怜玢
マヌケット
ニュヌス
分析
ツヌル
株匏スクリヌナヌ


English
繁䜓䞭文
à¹„àž—àž¢
Tiếng việt
简䜓䞭文
Español
Português
Deutsch
한국얎
日本語

tradingkey.logo
怜玢



Pharvaris NV

PHVS
りォッチリストに远加
29.879USD
-0.821-2.67%
取匕時間 ET15分遅れの株䟡
1.95B時䟡総額
損倱額盎近12ヶ月PER


Pharvaris NV

29.879
-0.821-2.67%
抂芁金融ディスカッション分析䌁業名

抂芁

金融

ディスカッション

分析

䌁業名

詳现情報 Pharvaris NV 䌁業名

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Pharvaris NVの䌁業情報


䌁業コヌドPHVS
䌚瀟名Pharvaris NV
䞊堎日Feb 05, 2021
最高経営責任者「CEO」Modig (Berndt B.A.E)
埓業員数- -
蚌刞皮類Ordinary Share
決算期末Feb 05
本瀟所圚地Emmy Noetherweg 2
郜垂LEIDEN
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Netherlands
郵䟿番号2333 BK
電話番号31712036410
りェブサむトhttps://pharvaris.com/
䌁業コヌドPHVS
䞊堎日Feb 05, 2021
最高経営責任者「CEO」Modig (Berndt B.A.E)

Pharvaris NVの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-1.57%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.84K
--
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
201.62K
+99.60%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
+54.39%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
106.11K
+48.26%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.28K
-5.73%
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-1.57%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.84K
--
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
201.62K
+99.60%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
+54.39%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
106.11K
+48.26%

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Thu, Feb 19
曎新時刻: Thu, Feb 19
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
General Atlantic LLC
11.53%
Fidelity Management & Research Company LLC
9.19%
Foresite Capital Management, LLC
6.86%
VenBio Partners LLC
6.66%
Viking Global Investors LP
5.24%
他の
60.52%
株䞻統蚈
株䞻統蚈
比率
General Atlantic LLC
11.53%
Fidelity Management & Research Company LLC
9.19%
Foresite Capital Management, LLC
6.86%
VenBio Partners LLC
6.66%
Viking Global Investors LP
5.24%
他の
60.52%
皮類
株䞻統蚈
比率
Private Equity
31.30%
Hedge Fund
20.13%
Investment Advisor
18.48%
Investment Advisor/Hedge Fund
10.17%
Venture Capital
4.94%
Individual Investor
4.89%
Research Firm
0.63%
Pension Fund
0.07%
Bank and Trust
0.07%
他の
9.33%

機関投資家保有株


曎新時刻: Wed, Apr 1
曎新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2026Q1
165
59.26M
90.60%
-451.33K
2025Q4
152
61.74M
96.38%
+11.01M
2025Q3
118
49.64M
77.50%
-950.63K
2025Q2
125
52.21M
81.51%
-1.38M
2025Q1
125
53.89M
99.06%
+200.61K
2024Q4
123
53.45M
98.98%
+218.03K
2024Q3
114
53.86M
99.73%
+1.03M
2024Q2
83
52.08M
96.43%
-141.66K
2024Q1
76
49.63M
98.30%
-831.88K
2023Q4
69
47.76M
94.74%
+8.60M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
General Atlantic LLC
8.03M
12.54%
--
--
Dec 31, 2025
Fidelity Management & Research Company LLC
6.40M
9.99%
--
--
Dec 31, 2025
Foresite Capital Management, LLC
4.78M
7.46%
--
--
Dec 31, 2025
VenBio Partners LLC
4.64M
7.24%
--
--
Dec 31, 2025
Viking Global Investors LP
3.65M
5.7%
--
--
Dec 31, 2025
EQT Partners AB
3.42M
5.35%
--
--
Dec 31, 2025
Deerfield Management Company, L.P.
3.13M
4.88%
+683.58K
+27.99%
Dec 31, 2025
Bain Capital Life Sciences Investors, LLC
2.80M
4.37%
-379.19K
-11.92%
Dec 31, 2025
Wellington Management Company, LLP
1.91M
2.98%
+171.05K
+9.86%
Dec 31, 2025
Commodore Capital LP
1.89M
2.95%
-529.03K
-21.87%
Dec 31, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
ALPS Medical Breakthroughs ETF
0.59%
iShares MSCI Netherlands ETF
0.23%
SPDR S&P International Small Cap ETF
0.08%
iShares MSCI Europe Small-Cap ETF
0.04%
iShares MSCI EAFE Small-Cap ETF
0.02%
Fidelity Nasdaq Composite Index ETF
0.01%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0.01%
Avantis International Small Cap Equity ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
詳现を芋る
Virtus LifeSci Biotech Clinical Trials ETF
比率0.87%
ALPS Medical Breakthroughs ETF
比率0.59%
iShares MSCI Netherlands ETF
比率0.23%
SPDR S&P International Small Cap ETF
比率0.08%
iShares MSCI Europe Small-Cap ETF
比率0.04%
iShares MSCI EAFE Small-Cap ETF
比率0.02%
Fidelity Nasdaq Composite Index ETF
比率0.01%
Xtrackers MSCI Eurozone Hedged Eqty ETF
比率0.01%
Avantis International Small Cap Equity ETF
比率0%
First Trust IPOX Europe Equity Opportunities ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™